Home › Funds › BAKER BROS. ADVISORS LP › DNLI

BAKER BROS. ADVISORS LP position in DNLI

DENALI THERAPEUTICS INC · Health Care

BAKER BROS. ADVISORS LP reported holding 3,734,336 shares of DNLI (DENALI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$96.0M, representing 0.50% of its reported portfolio and ranking #27 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed DNLI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)3.73M sh
Reported value held$96.05M
Portfolio Weight0.50%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's DNLI position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in DNLI in Q3 2023 at 2,292,003 shares (US$47.3M). The position peaked in Q3 2024 at 3,731,695 shares, worth US$108.7M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 9 time(s). The most recent filing (Q2 2026) shows 3,734,336 shares valued at US$96.0M. Notable position changes include a 43% increase in Q1 2024 (shares rose 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.29M $47.28M New
Q4 2023 2.61M $55.95M Add
Q1 2024 3.73M $76.57M Add
Q2 2024 3.73M $86.65M Hold
Q3 2024 3.73M $108.70M Hold
Q4 2024 3.73M $76.05M Hold
Q1 2025 3.73M $50.73M Hold
Q2 2025 3.73M $52.21M Hold
Q3 2025 3.73M $54.18M Hold
Q4 2025 3.73M $61.61M Hold
Q1 2026 3.73M $71.65M Hold
Q2 2026 3.73M $96.05M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DNLI and 13F data

DNLI (DENALI THERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in DNLI — the largest reported positions include Temasek Holdings (US$180.4M), Temasek Holdings (Private) Ltd (US$180.4M), Casdin Capital (US$52.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DNLI

All DNLI fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held DNLI?

BAKER BROS. ADVISORS LP has disclosed DNLI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BAKER BROS. ADVISORS LP's current position in DNLI?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 3.73M shares of DNLI (DENALI THERAPEUTICS INC), valued at $96.05M, representing 0.50% of its reported portfolio and ranking #27.

Has BAKER BROS. ADVISORS LP been buying or selling DNLI?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in DNLI. The position peaked in Q3 2024 at 3.73M shares.

Which other funds hold DNLI?

Other major institutional holders of DNLI include Temasek Holdings, Temasek Holdings (Private) Ltd, Casdin Capital, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.